EDIT
What one share of Editas Medicine holds
Biological Products, (No Diagnostic Substances)
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing.
Editas Medicine’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.46 |
|---|---|
| Profit | −$0.73 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.19 |
| Cash and investments | $2.16 |
| Debt | $0.57 |
| Book value | $1.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.19 | −$3.02 | $0.11 | −$1.67 | — | $3.76 |
| 2017 | $0.34 | −$2.98 | $0.05 | −$0.28 | — | $4.68 |
| 2018 | $0.68 | −$2.33 | $0.10 | −$1.07 | — | $4.84 |
| 2019 | $0.41 | −$2.68 | $0.12 | −$0.94 | — | $4.83 |
| 2020 | $1.55 | −$1.98 | $0.12 | −$3.19 | — | $6.29 |
| 2021 | $0.38 | −$2.85 | $0.12 | −$2.54 | — | $8.09 |
| 2022 | $0.29 | −$3.21 | $0.06 | −$2.64 | — | $5.24 |
| 2023 | $1.03 | −$2.02 | $0.06 | −$1.80 | — | $4.27 |
| 2024 | $0.39 | −$2.88 | $0.11 | −$2.66 | — | $1.62 |
| 2025 | $0.46 | −$1.80 | $0.01 | −$1.87 | — | $0.28 |